Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those …

MD Savvidou, KY Christina, LC Harland… - American journal of …, 2006 - Elsevier
OBJECTIVE: This study was undertaken to determine whether maternal serum concentration
of the angiogenic factor vascular endothelial growth factor (VEGF) and its circulating
antagonist, soluble fms-like tyrosine kinase 1 (sFlt-1), which have been implicated in the
pathogenesis of preeclampsia (PE), are altered in pregnancies that subsequently develop
PE and in those with established fetal growth restriction (FGR). STUDY DESIGN: Three
groups of healthy pregnant women at 23 to 25 weeks of gestation were examined: group A …